A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.

Summary

This study will determine the maximum tolerated dose, and assess the safety, tolerability and pharmacokinetics of R1530 administered orally to patients with advanced or metastatic solid tumors. R1530 will be administered daily for 14 days at the starting dose; this dose will be escalated in subsequent cohorts of patients, after a satisfactory assessment of safety and tolerability of the previous dose, until the maximum tolerated dose is reached. The anticipated time on study treatment is until disease progression, and the target sample size is \<100 individuals.

Timeline

Start

2005-10

Primary completion

2009-02

Completion

2009-02

Drugs

Indications